Qual é o preço para Apexigen, Inc. (APGN)

O preço para Apexigen, Inc. (APGN) é $0.385

Qual é a capitalização de mercado para Apexigen, Inc. (APGN)

A capitalização de mercado para Apexigen, Inc. (APGN) é $2.86M

Histórico de Preços de Apexigen, Inc. (APGN)

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Ano	Desempenho
2023	-63.18%
2022	-89.52%
2021	0.00%

Ano

Desempenho

2023

-63.18%

2022

-89.52%

2021

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Empresa

Preço da ação

Variação 1a%

País